Bristol-Myers, Pharmacyclics and Janssen collaborate for new non-hodgkin lymphoma drug
Opdivo (nivolumab) is BMS’s investigational PD-1 immune checkpoint inhibitor, while Imbruvica (ibrutinib) is an oral Bruton’s tyrosine kinase (BTK) inhibitor co-developed and co-marketed by Pharmacyclics and Janssen. The
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.